Enlivex Therapeutics Ltd. (ENLV.TA)
ILA 433.2
(5.2%)
ILA 433.2
(5.2%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -25.15 Million USD | 2.5% |
| 2022 | -25.79 Million USD | -33.75% |
| 2021 | -19.28 Million USD | -97.12% |
| 2020 | -9.78 Million USD | -13.53% |
| 2019 | -8.61 Million USD | -62.65% |
| 2018 | -5.29 Million USD | 11.02% |
| 2017 | -5.95 Million USD | 62.47% |
| 2016 | -15.86 Million USD | -2.52% |
| 2015 | -15.47 Million USD | -118.59% |
| 2014 | -7.08 Million USD | -516.72% |
| 2013 | -1.14 Million USD | -407.96% |
| 2012 | -226 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -4.15 Million USD | 59.84% |
| 2024 Q2 | -2.98 Million USD | 28.07% |
| 2023 Q2 | -6.64 Million USD | 1.98% |
| 2023 Q1 | -6.78 Million USD | 13.54% |
| 2023 Q3 | -5.62 Million USD | 15.36% |
| 2023 Q4 | -10.33 Million USD | -83.64% |
| 2023 FY | -25.15 Million USD | 2.5% |
| 2022 Q2 | -5.87 Million USD | 8.32% |
| 2022 Q3 | -5.67 Million USD | 3.3% |
| 2022 Q4 | -7.84 Million USD | -38.19% |
| 2022 FY | -25.79 Million USD | -33.75% |
| 2022 Q1 | -6.4 Million USD | 18.04% |
| 2021 Q4 | -7.81 Million USD | -102.23% |
| 2021 FY | -19.28 Million USD | -97.12% |
| 2021 Q3 | -3.86 Million USD | -1.47% |
| 2021 Q2 | -3.8 Million USD | -0.16% |
| 2021 Q1 | -3.8 Million USD | -2.84% |
| 2020 Q1 | -1.89 Million USD | 33.22% |
| 2020 Q4 | -3.69 Million USD | -88.72% |
| 2020 Q3 | -1.95 Million USD | 12.27% |
| 2020 FY | -9.78 Million USD | -13.53% |
| 2020 Q2 | -2.23 Million USD | -17.77% |
| 2019 Q2 | -1.29 Million USD | 45.09% |
| 2019 FY | -8.61 Million USD | -62.65% |
| 2019 Q4 | -2.83 Million USD | -33.85% |
| 2019 Q3 | -2.12 Million USD | -63.53% |
| 2019 Q1 | -2.36 Million USD | -14.22% |
| 2018 Q4 | -2.06 Million USD | -66.64% |
| 2018 FY | -5.29 Million USD | 11.02% |
| 2018 Q1 | -1.14 Million USD | -94.88% |
| 2018 Q2 | -848 Thousand USD | 25.74% |
| 2018 Q3 | -1.24 Million USD | -46.34% |
| 2017 Q2 | -1.65 Million USD | 37.46% |
| 2017 Q1 | -2.64 Million USD | 14.12% |
| 2017 FY | -5.95 Million USD | 62.47% |
| 2017 Q4 | -586 Thousand USD | 45.64% |
| 2017 Q3 | -1.07 Million USD | 34.71% |
| 2016 Q1 | -4.49 Million USD | 7.06% |
| 2016 Q4 | -3.07 Million USD | 32.85% |
| 2016 Q3 | -4.57 Million USD | -23.0% |
| 2016 Q2 | -3.72 Million USD | 17.14% |
| 2016 FY | -15.86 Million USD | -2.52% |
| 2015 Q3 | -3.58 Million USD | 4.04% |
| 2015 Q2 | -3.73 Million USD | -12.66% |
| 2015 Q4 | -4.83 Million USD | -34.74% |
| 2015 Q1 | -3.31 Million USD | -3.78% |
| 2015 FY | -15.47 Million USD | -118.59% |
| 2014 Q3 | -2.13 Million USD | -91.55% |
| 2014 Q4 | -3.19 Million USD | -50.09% |
| 2014 Q1 | -641 Thousand USD | 18.24% |
| 2014 Q2 | -1.11 Million USD | -73.48% |
| 2014 FY | -7.08 Million USD | -516.72% |
| 2013 Q3 | -192 Thousand USD | -43.28% |
| 2013 FY | -1.14 Million USD | -407.96% |
| 2013 Q2 | -134 Thousand USD | 0.0% |
| 2013 Q4 | -784 Thousand USD | -308.33% |
| 2012 FY | -226 Thousand USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Matricelf Ltd | -12.59 Million ILA | -99.674% |